About the Journal


The International Journal of Molecular and Immuno Oncology (IJMIO) is dedicated to providing a platform for highlighting novel and relevant research and exchange of knowledge at the crossroads of bench and bedside research. The goal is to provide information in an understandable format for clinicians and keep up with the fast-paced developments in Molecular Biology and Immunology related to Oncology.

IJMIO is a peer-reviewed Quarterly journal that is published both online and in print jointly by Molecular Oncology Society and Immuno Oncology Leadership Network. It is published by Scientific Scholar. The journal’s full text is available online at https://ijmio.com. IJMIO is an Open Access journal, and online access to full text articles is provided at no charge for non-commercial use. The journal does not charge for submission or acceptance of manuscripts.

IJMIO employs the highest standards in publishing, backed by the years of experience of the Molecular Oncology Society and Immuno Oncology Leadership Network. The journal follows stringent peer-review and editorial policies that allow for the selection of high quality work to be published. All manuscripts are evaluated by peer-review for their quality of science (including novelty, technical methodology, and integrity). The editorial policy is to require all authors to disclose any relevant financial associations and declare that financial interests have not influenced the content of the manuscript being published. This is in keeping with the high ethical standards we strive to ensure for all work published in IJMIO.

Focus and Scope

The International Journal of Molecular and Immuno Oncology (IJMIO) is dedicated to providing a platform for highlighting novel and relevant research and exchange of knowledge at the crossroads of bench and bedside research. The goal is to provide information in an understandable format for clinicians and keep up with the fast-paced developments in Molecular Biology and Immunology related to Oncology.

IJMIO is a peer-reviewed Quarterly journal that is published both online and in print jointly by Molecular Oncology Society and Immuno Oncology Leadership Network. It is published by Scientific Scholar. The journal’s full text is available online at https://ijmio.com. IJMIO is an Open Access journal, and online access to full text articles is provided at no charge for non-commercial use. The journal does not charge for submission or acceptance of manuscripts.

Peer Review Process

IJMIO employs the highest standards in publishing, backed by the years of experience of the Molecular Oncology Society and Immuno Oncology Leadership Network. The journal follows a double-blind peer-review process, wherein the reviewers and authors are unaware of each other's identity and editorial policies that allow for the selection of high quality work to be published. All manuscripts are evaluated by peer-review for their quality of science (including novelty, technical methodology, and integrity). The editorial policy is to require all authors to disclose any relevant financial associations and declare that financial interests have not influenced the content of the manuscript being published. This is in keeping with the high ethical standards we strive to ensure for all work published in IJMIO.

Editorial Team

The editorial board comprises of a panel of international experts in International Journal of Molecular and Immuno Oncology from around the globe. Our editorial board members provide their expertise and guidance in shaping the content and direction of the journal.

About the Emeritus Editors

Dr. Purvish M. Parikh MD, DNB, FICP, PHD, ECMO, CPI, MBA

Dr. Purvish M. Parikh is,
1. Director of Precision Oncology & Research, Asian Cancer Institute
2. Board Member, Maharashtra University of Health Sciences
3. Executive Director, Indian Cooperative Oncology Network
4. Director of Clinical Research and Education, BSES Municipal Hospital
5. Past President, SAARC Federation for Oncologists
6. Past President, Indian Society of Medical & Pediatric Oncology
7. Emeritus Editor, South Asian Journal of Cancer & International Journal of Molecular and Immuno-Oncology.
8. Passionate about Digital Health & Medico-Legal Issues.
9. Unconventional Educator
10.Author of 19 books; 36 chapters in books; 200+ scientific articles

About the Editor-In-Chief

Dr. Randeep Singh MD, DM, ECMO, FCCP

Dr. Singh currently is working as Senior consultant and unit head at Artemis hospitals, Gurugram. He also owns ONCOMED clinic at Hauz Khas, Delhi. He has been trained extensively in the management of cancer patients at the prestigious Tata Memorial Hospital (TMH), Mumbai. He did his Doctorate (DM: Medical Oncology) from Tata Memorial Hospital, Mumbai and then worked as a consultant at TMH, Mumbai with the solid tumor-working group before joining Max group of hospitals. He worked as a Consultant with Max Healthcare for five years. Thereafter he was heading the department of Medical Oncology at HCG cancer center, Delhi before joining ARTEMIS Hospitals, Gurgaon. His key area of interest are lung cancer , gastrointestinal and breast cancer.

Dr. Singh has more than 40 publications in national and international journals of high impact factor. He has also attended and presented various scientific papers in national and international journals. He is a distinguished faculty at various national and international conferences. He currently serves as Joint Secretary at Indian Society Medical & Pediatric oncology (ISMPO) . He is a co-founder member of International CME organization and executive member of various national organization’s such as ICON (Indian Co-Operative Oncology Network), ISMPO (Indian Society of Medical & Pediatric Oncology), Delhi Oncology Forum . He is also associated with international societies such as ESMO (European Society of Medical Oncology) & ASCO (American Society of Clinical Oncology)

Facts about the Journal

Scope of the journal

IJMIO is a peer-reviewed journal that highlights latest developments, approaches, and discoveries in basic, clinical and translational oncology. The journal reviews and accepts original clinical and laboratory-based research manuscripts as well as invited reviews focused on molecular biological and immunological aspects of oncology. Articles addressing contemporary advances and challenges faced in molecular and immuno oncology in developing nations are also strongly encouraged.

Key areas covered by the journal include
  • Biomarkers and individualized therapy
  • Nanotechnology and other technological advances
  • Cancer genetics and epigenetics
  • Cancer micro-environment and cell biology
  • Immunological aspects of tumorigenesis
  • Molecular and immunological therapies
  • Clinical trials
Section Policies

This journal publishes manuscripts in the following sections

  • Original Articles
  • Case Reports
  • Review Articles
  • Educational Forum
  • Editorial
  • New Drug Update
  • Letter to The Editor
  • Short Communication
  • Corrigendum
  • Brief Commentary
  • Consensus Statement
  • Other

All manuscripts submitted through all the sections are peer reviewed prior to acceptance and indexed once published

Open Access Policy and Creative Commons Licensing

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Archiving

This journal utilizes the LOCKSS system to create a distributed archiving system among participating libraries and permits those libraries to create permanent archives of the journal for purposes of preservation and restoration.

Plagiarism Policy

We have plagiarism check available on our Editors and Reviewer’s panel in the manuscript management system. We encourage our editors and reviewers to use the plagiarism check. Any manuscript with plagiarism will be rejected immediately.

Publisher

International Journal of Molecular and Immuno Oncology is a publication of Scientific Scholar, a USA based publisher of scientific journals.

Imaging Science Today was founded in 2011 by a group of practicing doctors and industry specialists and from 2017 its scientific journal publishing business was brought under a new umbrella of Scientific Scholar. It is a well-respected medical publisher that fully supports many of the popular open access models and all the aspects of the scientific journal publishing through its peer-review management system- Scientific Scholar and Open Access platform. The headquarter of Scientific Scholar is in Rochester, NY, USA and has a subsidiary arm in India.

Scientific Scholar currently publishes prestigious journals like American Journal of Interventional Radiology, American Journal of Sonography and American Journal of Ophthalmic Clinical Trials and is growing in its portfolio.

Crossref
Creative Commons
Open Access
Portico